| __timestamp | BioMarin Pharmaceutical Inc. | Protagonist Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 1860000 |
| Thursday, January 1, 2015 | 402271000 | 2963000 |
| Friday, January 1, 2016 | 476593000 | 6961000 |
| Sunday, January 1, 2017 | 554336000 | 11779000 |
| Monday, January 1, 2018 | 604353000 | 13697000 |
| Tuesday, January 1, 2019 | 680924000 | 15749000 |
| Wednesday, January 1, 2020 | 737669000 | 18638000 |
| Friday, January 1, 2021 | 759375000 | 27196000 |
| Saturday, January 1, 2022 | 854009000 | 31739000 |
| Sunday, January 1, 2023 | 937300000 | 33491000 |
| Monday, January 1, 2024 | 1009025000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, effective cost management is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of BioMarin Pharmaceutical Inc. and Protagonist Therapeutics, Inc. over the past decade. From 2014 to 2023, BioMarin's SG&A expenses have surged by over 200%, reflecting its aggressive growth strategy and market expansion. In contrast, Protagonist Therapeutics, while smaller in scale, has seen its SG&A expenses grow by nearly 1,700%, indicating its rapid development phase.
BioMarin's expenses peaked in 2023, reaching approximately 937 million, a testament to its established market presence. Meanwhile, Protagonist's expenses, though significantly lower, highlight its dynamic growth trajectory. This comparison underscores the diverse strategies employed by biotech firms in managing operational costs, offering valuable insights into their financial health and strategic priorities.
SG&A Efficiency Analysis: Comparing Johnson & Johnson and Protagonist Therapeutics, Inc.
Amgen Inc. and Protagonist Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Protagonist Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Genmab A/S and Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Neurocrine Biosciences, Inc. vs Protagonist Therapeutics, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Walgreens Boots Alliance, Inc.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alpine Immune Sciences, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs TG Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Xenon Pharmaceuticals Inc. vs Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc. or Agios Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Protagonist Therapeutics, Inc. vs Evotec SE: SG&A Expense Trends